adam feuerstein: The "next" Rituxan is going to be PCYC's ibrutinib, or so that's what the bulls say. 12:43 adam feuerstein: oral, too Rituxan sales $6.6 billion in 2010 .Sales of drugs to treat non-Hodgkin's lymphoma are set to more than double in value over the next decade.So ask yourself how much is Pharmacyclics worth?
Oh, how the mighty have fallen. PCYC was one of the top ten strongest stocks in the entire market along with MDVN and a few others. No matter what sector you follow, these are the stocks I look for when measuring strength. I would not read anymore into it other than the market we are in. Rodman does not have that much power, it was just bound to happen sooner or later. All the strongest stocks in the market have taken a hit, so all bets are of at the moment.